Nabriva Therapeutics Class Action

Nabriva TherapeuticsPublicly available records indicate that a class action lawsuit has been filed on behalf of investors in Nabriva Therapeutics (NASDAQ:NBRV) in connection to alleged securities law violations by NBRV. Fitapelli Kurta is interested in hearing from investors who have complaints regarding investments made in Nabriva Therapeutics between November 1, 2018 and April 30, 2019.

The class action complaint specifically alleges that during the period in question, NBRV provided false and/or misleading material information and/or failed to disclose adverse material information to the public, chiefly: that the company’s manufacturers did not abide by proper manufacturing practices; that the company’s manufacturers would fall under the scrutiny of the Food and Drug Administration as it considered a New Drug Application from the company; that the FDA was likely to decline to approve the company’s application for CONTEPO because of these failures in the company’s manufacturing processes; and that consequently the company’s statements to the public during the relevant period were false and misleading. The complaint alleges that when true facts emerged, investors suffered losses.

According to the company’s website, Nabriva Therapeutics is a clinical-stage biopharmaceutical company involved in the development of antibiotics for infectious diseases. Its product pipline includes Lefamulin, an antibiotic for the treatment of community-acquired bacterial pneumonia; BC-7013, a compound for the topical treatment of gram-positive infections; and CONTEPO, an intravenous antibiotic “with a broad spectrum of Gram-negative and Gram-positive activity.” The company was spun off from Sandoz GmbH Antibiotics Research Institute in 2006, opened in the United States in 2014, completed its initial public offering in 2015, and re-domiciled its headquarters to Dublin, Ireland in 2017. The company trades on the Nasdaq Exchange under the symbol NBRV.

A class action lawsuit has already been filed in connection with Nabriva Therapeutics. If you wish to serve as lead plaintiff in the NBRV lawsuit, you must move the Court no later than July 8, 2019. If you wish to join the litigation, please contact Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery does not require that you serve as a lead plaintiff.